ArticleAnnals of hematology2025
Efficacy of PR2-based immunotherapy in the treatment of diffuse large B-cell lymphoma-associated neurolymphomatosis: A report on two cases.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurolymphomatosis (NL) is a rare manifestation of lymphoma resulting from the infiltration of malignant lymphoma cells into the peripheral nervous system. When evaluating peripheral neuropathy, clinical suspicion of NL is highly necessary because its clinical symptoms vary and pathological diagnosis is often difficult. Imaging modalities carry a high sensitivity to diagnose NL. 18 F-flurodeoxyglucose positron emission tomography-computed tomography (18 F-FDG PET/CT), with a diagnostic sensitivity of over 90%, as well as Magnetic resonance imaging (MRI) neurography, has become the leading diagnostic modalities for NL diagnosis, staging, and treatment response assessment. At present, the prognosis of NL is usually poor, and its treatment is also challenging, with few patients benefiting from the currently available treatment measures. The present report discusses two cases of diffuse large B-cell lymphoma-associated NL. They presented with painful polyneuropathy/polyradiculopathy, and imaging examinations such as MRI and 18 F-FDG PET/CT indicated related neuropathy. Both cases were treated with PR2-based immunotherapy (anti-PD-1 tirelizumab 200 mg d1, rituximab 375 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.